Pharmacokinetics of metformin in patients with gastrointestinal intolerance

Abstract

AimsTo assess potential causes of metformin intolerance, including altered metformin uptake from the intestine, increased anaerobic glucose utilization and subsequent lactate production, altered serotonin uptake, and altered bile acid pool.MethodsFor this pharmacokinetic study, we recruited 10 severely intolerant and 10 tolerant individuals, matched for age, sex and body mass index. A single 500‐mg dose of metformin was administered, with blood sampling at 12 time points over 24 hours. Blood samples were analysed for metformin, lactate, serotonin and bile acid concentrations, and compared across the phenotypes.ResultsThe intolerant individuals were severely intolerant to 500 mg metformin. No significant difference was identified between tolerant and intolerant cohorts in metformin pharmacokinetics: median (interquartile range [IQR]) peak concentration 2.1 (1.7‐2.3) mg/L and 2.0 (1.8‐2.2) mg/L, respectively (P = .76); time to peak concentration 2.5 hours; median (IQR) area under the curve (AUC)0–24 16.9 (13.9‐18.6) and 13.9 (12.9‐16.8) mg/L*h, respectively (P = .72). Lactate concentration peaked at 3.5 hours, with mean peak concentration of 2.4 mmol/L in both cohorts (95% CI 2.0‐2.8 and 1.8‐3.0 mmol/L, respectively), and similar incremental AUC0–24 in each cohort: tolerant cohort 6.98 (95% CI 3.03‐10.93) and intolerant cohort 4.47 (95% CI –3.12‐12.06) mmol/L*h (P = .55). Neither serotonin nor bile acid concentrations were significantly different.ConclusionsDespite evidence of severe intolerance in our cohort, there was no significant difference in metformin pharmacokinetics or systemic measures of lactate, serotonin or bile acids. This suggests that metformin intolerance may be attributable to local factors within the lumen or enterocyte.

GDF15 mediates the effects of metformin on body weight and energy balance

“…Circulating metformin levels achieved in both genotypes were identical (Extended Data Fig. 5d) and consistent with the high end of the human therapeutic range 14 . Metformin significantly increased insulin sensitivity as assessed by the area under the plasma glucose curve with no significant effect of genotype ( Fig.…”

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

“…A recent 2018 pharmacokinetic study reported the absence of significant differences in the absorption, distribution or elimination of metformin between tolerant and intolerant individuals, suggesting the involvement of local factors within the intestinal lumen or enterocytes 218 . Interestingly, the association between metformin gastrointestinal intolerance with genetic variations in the metformin transporter OCT1 and serotonin transporter SERT supports the concept that metformin induces alterations in gastrointestinal physiology.…”

Metformin: A Prospective Alternative for the Treatment of Chronic Pain

“…Pharmacokinetic-pharmacodynamic modeling has shown a correlation between the time course of metformin concentrations in the portal vein and gut wall and hypoglycemic effect, instead of drug concentrations in liver ( Stepensky et al., 2002 ; Sun et al., 2011 ). The time to reach maximal plasma concentrations in human beings after metformin administration (T max ) is 1.5 to 2.7 h ( Caillé et al., 1993 ; Sambol et al., 1996 ; Wei et al., 2009 ; Zhang et al., 2014 ; McCreight et al., 2018 ), which follows a multiphasic pattern ( Graham et al., 2011 ), giving a peak plasma concentration (C max ) of 1.1 to 2.5 µg/ml ( Wei et al., 2009 ; Zhang et al., 2014 ; Dias et al., 2019 ), and a steady-state concentration range of 0.3 to 1.5 µg/ml (see Table 2 ). Plasma protein binding is negligible, and the drug is not metabolized ( Scheen, 1996 ).…”